FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?

E-resources

PDF

Full text

Peer reviewed Open access

FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?

Milunović, Vibor; Mišura Jakobac, Karla; Kursar, Marin; Mandac Rogulj, Inga; Ostojić Kolonić, Slobodanka

European journal of haematology, September 2019, Volume: 103, Issue: 3

Journal Article

ECHELON‐1 study is a randomized open‐labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow‐up of 24.6 months, it has met its primary endpoint the reduction of modified progression‐free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in‐depth insight of pros and cons of this novel, promising but ultimately controversial regimen.

Keep searching

Author

Milunović, Vibor | Mišura Jakobac, Karla | Kursar, Marin | Mandac Rogulj, Inga | Ostojić Kolonić, Slobodanka

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme